News

FDA approved Bridion (sugammadex) injection today – after a long wait by Merck & Co. – to reverse the effects of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide, used during certain types of surgery.

Valeant Pharmaceuticals just entered into a new fulfillment agreement with Walgreens and says it will reduce prices of its branded prescription-based dermatological and ophthalmological products such as Jublia by 10 percent.

Federal antitrust officials are determining how, and if, transactions will move forward. Here's a roadmap of what's ahead in 2016.

Here are four critical considerations that are integral to successful implementation of a value-based payment model.

FDA granted accelerated approval to Alecensa (alectinib) for the treatment of people with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.

Hospital stays were shorter for patients treated with Xarelto (rivaroxaban) in a new study, compared to those receiving standard anticoagulants.

We asked four experts what managed healthcare executives need to know about the mental health coverage requirements.

Several studies have demonstrated that telemedicine programs of different types can yield the same or better results than more traditional diabetes interventions.

How can plans and providers turn the dial up on member engagement? We asked three experts to weigh in.

Boehringer Ingelheim recently began a clinical trial to assess the safety and tolerability of adding on pirfenidone to Ofev (nintedanib) for idiopathic pulmonary fibrosis patients.

FDA is warning about ketoacidosis and urinary tract infections associated with the relatively new class of type 2 diabetes medicines called sodium-glucose cotransporter-2 (SGLT2) inhibitors such as Invokana and Jardiance.

Population health management, one of the most pressing priorities for executives today, requires careful planning and strategy. Here are some tips.

FDA has approved recombinant von Willebrand factor (Vonvendi, Baxalta) for use in adults who have von Willebrand disease.

FDA has approved methylphenidate hydrochloride (QuilliChew ER, Pfizer) extended-release chewable tablets for the treatment of ADHD in children.

Genetically engineered chickens were needed to produce Kanuma (sebelipase alfa), newly approved by FDA to treat lysosomal acid lipase deficiency (LAL-D), a genetic and progressive ultra-rare metabolic disease in which patients suffer multi-organ damage and premature death.

Here are the top 3 value-based healthcare developments of 2015 and the top 3 ways to advance value-based care in 2016.

Pharmacists in California and Oregon will soon be able to prescribe birth control.

Information sharing, coordination are key to realizing the genomic revolution in medicine.

Price, comorbidities are as important as TKI choice for patients with chronic myeloid leukemia

Scientists explore innovative delivery systems that might one day treat hemophilia and other blood diseases

Researchers see promising early clinical trials with checkpoint-inhibitor therapies, opening the door for checkpoint-blockade combo therapies.

The Pulmonary Fibrosis Foundation and Boehringer Ingelheim’s new five-year partnership, aims to raise awareness of pulmonary fibrosis, provide disease education and advance care and funding research for the PF community

As researchers uncover biomarkers for cancer subtypes, collaboration between researchers, pathologists and physicians will improve accurate diagnosis of lymphoma subtypes.

Next-generation gene sequencing and other advanced technologies for personalized medicine may soon identify biomarkers that will improve treatment response and long-term toxicity risks for childhood cancer patients.

AML’s genetic complexity raises concerns about long-term prospects of single mutation-targeting agents

Myeloma combination treatments get the once-over by leading cancer expert.

A new US Congressional report about the price of hepatitis C drug Sovaldi, along with a new class action lawsuit against Blue Cross Blue Shield involving Harvoni coverage, are the latest in a series of controversies surrounding the 2 drugs.

As technology has evolved, the potential of population health management as a tool to improve quality and reduce costs has expanded.